Dec 13, 2021 / 04:00PM GMT
Robert Blum - Lytham Partners, LLC - Analyst
All right. Hello, everyone, and thank you all for joining us during the Lytham Partners winter 2021 investor conference and what we are calling our 2022 vision event. My name is Robert Blum, Managing Partner of Lytham Partners. And during this fireside chat, we welcome INVO Bioscience, ticker symbol of INVO on the NASDAQ; and their CEO, Mr. Steve Shum. I'm going to dive into questions in just a moment, but I want to remind everyone that if you would like to arrange a one-on-one meeting with Steve, please send me an email; that's [email protected]. And I will go ahead and get you taken care of.
So Steve, welcome. Let's get started.
Steve Shum - INVO Bioscience, Inc. - CEO
Thank you, Robert.
Questions and Answers:
Robert Blum - Lytham Partners, LLC - AnalystPerfect. So help set the stage for the viewers here. INVO has developed an alternative solution to in vitro fertilization or IVF. Walk through the INVO process and how it differs from IVF.